Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by Clal Insurance Enterprises Holdings Ltd

Clal Insurance Enterprises Holdings Ltd boosted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 12.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,962,773 shares of the company’s stock after purchasing an additional 4,418,961 shares during the period. Teva Pharmaceutical Industries makes up 7.7% of Clal Insurance Enterprises Holdings Ltd’s portfolio, making the stock its 3rd biggest position. Clal Insurance Enterprises Holdings Ltd owned 3.44% of Teva Pharmaceutical Industries worth $859,935,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. FMR LLC raised its stake in Teva Pharmaceutical Industries by 49.5% during the third quarter. FMR LLC now owns 62,740,763 shares of the company’s stock worth $1,130,589,000 after acquiring an additional 20,762,226 shares during the period. Lingotto Investment Management LLP boosted its stake in Teva Pharmaceutical Industries by 2.6% in the fourth quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company’s stock valued at $599,320,000 after acquiring an additional 688,862 shares during the period. Migdal Insurance & Financial Holdings Ltd. boosted its stake in Teva Pharmaceutical Industries by 2.2% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company’s stock valued at $573,822,000 after acquiring an additional 569,412 shares during the period. State Street Corp boosted its stake in Teva Pharmaceutical Industries by 10.0% in the third quarter. State Street Corp now owns 19,500,683 shares of the company’s stock valued at $351,402,000 after acquiring an additional 1,778,268 shares during the period. Finally, AustralianSuper Pty Ltd boosted its stake in Teva Pharmaceutical Industries by 16.8% in the fourth quarter. AustralianSuper Pty Ltd now owns 9,222,695 shares of the company’s stock valued at $203,268,000 after acquiring an additional 1,329,319 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Up 0.8 %

Teva Pharmaceutical Industries stock opened at $16.45 on Friday. The company’s fifty day simple moving average is $19.54 and its 200-day simple moving average is $18.46. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 12 month low of $12.51 and a 12 month high of $22.80. The stock has a market cap of $18.64 billion, a P/E ratio of -11.34, a P/E/G ratio of 1.44 and a beta of 0.71.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now directly owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.55% of the company’s stock.

Analyst Ratings Changes

TEVA has been the subject of a number of research reports. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Barclays reduced their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. Piper Sandler boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. Finally, UBS Group reduced their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $23.57.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.